Home » Topics » Regulatory » EMA

EMA
RSS

FDA clears design of phase III oritavancin trials SOLO-1 and -2

Dec. 1, 2010

New Juvista formulation for children significantly improves scar appearance

Nov. 23, 2010

CIS Bio withdraws E.U. marketing authorization for NeoSpect

Nov. 23, 2010

EMA's COMP recommends orphan status for paquinimod in systemic sclerosis

Nov. 18, 2010

EMA accepts Pixuvri MAA for non-Hodgkin's lymphoma for review

Nov. 18, 2010

Roche reports on third quarter of 2010

Nov. 18, 2010

EMA approves Cell Therapeutics' pediatric investigation plan for Pixuvri

Nov. 17, 2010

EMA orphan drug status for SBC-102 in LAL deficiency / News in Context

Nov. 17, 2010

EMA committee recommends orphan drug status for ThermoDox in primary liver cancer

Nov. 12, 2010

Schering-Plough Europe withdraws MAA for Zenhale

Nov. 11, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...